# 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

> **NCT04315246** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Y-mAbs Therapeutics**

## Conditions studied

- Leptomeningeal Metastasis
- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** radiolabeled DPTA-omburtamab

## Key facts

- **NCT ID:** NCT04315246
- **Lead sponsor:** Y-mAbs Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-08-31
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business priorities
- **Last updated:** 2022-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04315246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04315246, "177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04315246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*